AstraZeneca Stock News

TORONTO--(BUSINESS WIRE)--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for Canadians living with and beyond the disease. Announced at Breast Cancer Canada's Canadian Night reception during the European Society for Medical Oncology (ESMO) Congress in Madrid, the funding will ...

AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, and whose disease has progressed on or after platinum-based ch...

AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment ​for adults with immunoglobulin A nephropathy, a ‌rare kidney disease that can lead to renal failure.

Jefferies, the investment bank, estimates a 59% probability that AstraZeneca PLC (LSE:AZN, NYSE:AZN)'s zibotentan succeeds in the phase 3 ZENITH-HP kidney disease trial, which is due to report in the first half of 2027. The broker rates AstraZeneca, the FTSE 100 drugmaker, a 'buy' with a price target of 17,500p, which implies 41% upside from Monday's close of 12,446p.

Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% ​of patients with a type of chronic inflammatory disorder ‌of the esophagus.